Table 1 Baseline characteristics of the study cohort (n = 148)

Age, mean (SD)

47.6 (8.5)

Sex (woman), n (%)

132 (89.2%)

Years of evolution, mean (SD)

28.3 (12.3)

Diagnosis, n (%)

Episodic migraine

56 (37.8%)

Chronic migraine

92 (62.2%)

Anti-CGRP, n (%)

Erenumab

93 (62.8%)

Galcanezumab

34 (23%)

Fremanezumab

21 (14.2%)

Total working hours, mean (SD)

37.1 (8.2)

Absenteeism, median (Q1-Q3)

0 (12.3–0)

Presentism, median (Q1-Q3)

40 (66.3–0)